… Lung cancer is the leading cause of cancer death among men and women in North America.
In advanced non–small-cell lung cancer, … -based therapy for non–small-cell lung cancer. …

… Erlotinib (Tarceva) is a specific epidermal growth factor … Gefitinib (Iressa) shares with
erlotinib both a common chemical … as a third-line therapy for non-small cell lung cancer (NSCLC) …

… Symptom improvement in lung cancer patients treated with erlotinib: quality of life
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …

… The EGFR is frequently expressed in a variety of epithelial tumors; non-small-cell lung
cancer (NSCLC) is among the epithelial cancers that are characterized by a generally high …

… cure in up to 16% of patients with stage III lung cancer [6]. Despite modest improvement in
survival and symptom relief provided by systemic therapy, … rash in erlotinib-treated lung cancer …

… Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …

… Erlotinib and gefitinib, two small molecular agents that target the tyrosine kinase domain of
the EGFR, were approved in many countries for the treatment … erlotinib, as first-line treatment …

… , erlotinib, at a standard oral daily dose of 150 mg, is licensed for the treatment of unselected
recurrent non-small cell lung cancer (… Erlotinib is well tolerated, with common toxicities …

… Erlotinib is a small molecule inhibitor of epidermal growth … with previously treated advanced
non-small cell lung cancer. Here, … trial of erlotinib (Tarceva Lung Cancer Survival Treatment). …

… Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell
lung cancer (… We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) …